GlucoTrack Total Current Liabilities vs Total Current Assets Analysis

GCTK Stock  USD 0.25  0.01  3.85%   
GlucoTrack financial indicator trend analysis is much more than just examining GlucoTrack latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlucoTrack is a good investment. Please check the relationship between GlucoTrack Total Current Liabilities and its Total Current Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.

Total Current Liabilities vs Total Current Assets

Total Current Liabilities vs Total Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlucoTrack Total Current Liabilities account and Total Current Assets. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between GlucoTrack's Total Current Liabilities and Total Current Assets is -0.24. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of GlucoTrack, assuming nothing else is changed. The correlation between historical values of GlucoTrack's Total Current Liabilities and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of GlucoTrack are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Total Current Liabilities i.e., GlucoTrack's Total Current Liabilities and Total Current Assets go up and down completely randomly.

Correlation Coefficient

-0.24
Relationship DirectionNegative 
Relationship StrengthInsignificant

Total Current Liabilities

Total Current Liabilities is an item on GlucoTrack balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of GlucoTrack are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.
Most indicators from GlucoTrack's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlucoTrack current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.Selling General Administrative is expected to rise to about 2.4 M this year, although the value of Issuance Of Capital Stock will most likely fall to about 5.2 M.
 2021 2022 2023 2024 (projected)
Cost Of Revenue42K23K13K12.4K
Reconciled Depreciation42K23K25K32.9K

GlucoTrack fundamental ratios Correlations

0.5-0.15-0.25-0.060.610.19-0.55-0.730.020.54-0.12-0.560.54-0.51-0.250.8-0.480.510.47-0.35-0.12-0.31-0.750.84-0.81
0.50.2-0.28-0.210.520.17-0.97-0.34-0.230.98-0.14-0.440.98-0.120.080.39-0.151.00.310.07-0.07-0.18-0.330.53-0.44
-0.150.2-0.45-0.510.0-0.06-0.180.41-0.570.270.00.070.270.19-0.22-0.370.090.2-0.050.54-0.1-0.340.31-0.270.25
-0.25-0.28-0.450.95-0.480.280.34-0.260.9-0.380.40.46-0.380.290.060.150.44-0.30.240.020.540.46-0.140.020.13
-0.06-0.21-0.510.95-0.430.480.3-0.350.98-0.340.530.47-0.340.250.010.250.41-0.240.35-0.030.610.55-0.230.130.02
0.610.520.0-0.48-0.43-0.24-0.66-0.5-0.40.63-0.52-0.780.63-0.90.040.59-0.920.540.37-0.56-0.56-0.67-0.650.72-0.66
0.190.17-0.060.280.48-0.240.020.00.520.020.920.570.020.26-0.350.060.330.120.640.190.750.570.020.040.16
-0.55-0.97-0.180.340.3-0.660.020.420.32-0.990.330.6-0.990.28-0.1-0.460.32-0.98-0.280.020.260.380.44-0.630.56
-0.73-0.340.41-0.26-0.35-0.50.00.42-0.39-0.350.240.54-0.350.51-0.17-0.950.42-0.34-0.480.40.190.280.97-0.940.88
0.02-0.23-0.570.90.98-0.40.520.32-0.39-0.370.540.43-0.370.20.010.30.36-0.260.37-0.140.610.59-0.270.18-0.03
0.540.980.27-0.38-0.340.630.02-0.99-0.35-0.37-0.27-0.541.0-0.240.010.42-0.290.980.290.04-0.23-0.38-0.380.57-0.49
-0.12-0.140.00.40.53-0.520.920.330.240.54-0.270.84-0.270.45-0.41-0.20.52-0.190.470.380.760.630.25-0.270.45
-0.56-0.440.070.460.47-0.780.570.60.540.43-0.540.84-0.540.64-0.36-0.540.69-0.480.080.550.60.590.56-0.630.79
0.540.980.27-0.38-0.340.630.02-0.99-0.35-0.371.0-0.27-0.54-0.240.010.42-0.290.980.290.04-0.23-0.38-0.380.57-0.49
-0.51-0.120.190.290.25-0.90.260.280.510.2-0.240.450.64-0.240.02-0.590.99-0.14-0.390.720.530.630.67-0.650.58
-0.250.08-0.220.060.010.04-0.35-0.1-0.170.010.01-0.41-0.360.010.020.00.020.09-0.38-0.18-0.230.15-0.060.04-0.28
0.80.39-0.370.150.250.590.06-0.46-0.950.30.42-0.2-0.540.42-0.590.0-0.510.40.55-0.43-0.2-0.33-0.950.95-0.85
-0.48-0.150.090.440.41-0.920.330.320.420.36-0.290.520.69-0.290.990.02-0.51-0.18-0.30.670.610.690.59-0.590.55
0.511.00.2-0.3-0.240.540.12-0.98-0.34-0.260.98-0.19-0.480.98-0.140.090.4-0.180.280.05-0.11-0.21-0.340.54-0.46
0.470.31-0.050.240.350.370.64-0.28-0.480.370.290.470.080.29-0.39-0.380.55-0.30.28-0.070.26-0.11-0.580.59-0.26
-0.350.070.540.02-0.03-0.560.190.020.4-0.140.040.380.550.040.72-0.18-0.430.670.05-0.070.150.090.42-0.430.47
-0.12-0.07-0.10.540.61-0.560.750.260.190.61-0.230.760.6-0.230.53-0.23-0.20.61-0.110.260.150.740.3-0.260.34
-0.31-0.18-0.340.460.55-0.670.570.380.280.59-0.380.630.59-0.380.630.15-0.330.69-0.21-0.110.090.740.44-0.410.43
-0.75-0.330.31-0.14-0.23-0.650.020.440.97-0.27-0.380.250.56-0.380.67-0.06-0.950.59-0.34-0.580.420.30.44-0.960.87
0.840.53-0.270.020.130.720.04-0.63-0.940.180.57-0.27-0.630.57-0.650.040.95-0.590.540.59-0.43-0.26-0.41-0.96-0.89
-0.81-0.440.250.130.02-0.660.160.560.88-0.03-0.490.450.79-0.490.58-0.28-0.850.55-0.46-0.260.470.340.430.87-0.89
Click cells to compare fundamentals

GlucoTrack Account Relationship Matchups

GlucoTrack fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding11.9M15.1M15.5M15.5M4.2M4.9M
Total Assets1.3M10.6M6.3M2.4M4.9M3.8M
Short Long Term Debt Total377.6K363K250K195K196K246.7K
Other Current Liab596.1K392K229K341K673K594.1K
Total Current Liabilities2.3M1.3M883K1.0M1.5M1.7M
Total Stockholder Equity(1.4M)9.0M5.2M1.2M3.2M3.4M
Property Plant And Equipment Net321.0K315K109K40K27K25.7K
Net Debt(41.0K)(9.5M)(5.8M)(2.1M)(4.3M)(4.1M)
Retained Earnings(90.7M)(93.4M)(97.5M)(101.9M)(109.9M)(104.4M)
Accounts Payable1.5M869K631K672K839K1.0M
Cash418.6K9.8M6.1M2.3M4.5M2.9M
Non Current Assets Total564.4K377K160K59K37K35.2K
Non Currrent Assets Other186.4K62K51K4K10K9.5K
Cash And Short Term Investments418.6K9.8M6.1M2.3M4.5M2.9M
Liabilities And Stockholders Equity1.3M10.6M6.3M2.4M4.9M3.8M
Non Current Liabilities Total421.8K279K227K195K196K186.2K
Other Current Assets21.4K56K43K67K376K394.8K
Other Stockholder Equity89.0M102.4M102.6M103.1M113.0M61.6M
Total Liab2.7M1.6M1.1M1.2M1.7M1.6M
Total Current Assets718.0K10.2M6.1M2.4M4.9M3.4M
Accumulated Other Comprehensive Income124.1K15K(6K)17K64K67.1K
Common Stock141.6K162.8K201K15K20K19K
Net Tangible Assets(1.4M)9.0M5.2M1.2M1.4M1.5M
Other Assets57K62K0.019K1.00.95
Property Plant Equipment321K315K109K40K36K34.2K
Long Term Debt190.4K197K210K195K196K212.0K
Net Invested Capital(1.2M)9.2M5.4M1.4M3.4M2.8M
Net Working Capital(1.6M)8.9M5.2M1.4M3.4M2.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlucoTrack is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlucoTrack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glucotrack Stock. Highlighted below are key reports to facilitate an investment decision about Glucotrack Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.91)
Return On Assets
(1.57)
Return On Equity
(5.41)
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.